Biotech entity
Every one of those 3 sits in a single category, pharma. Source depth averages 9.3 original sources per story, versus 3.5 across the same-window beat baseline. Of the tracked stories, 1 of 3 also mention Cidara Therapeutics, the most common co-covered peer.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 3 sits in a single category, pharma. Source depth averages 9.3 original sources per story, versus 3.5 across the same-window beat baseline. Of the tracked stories, 1 of 3 also mention Cidara Therapeutics, the most common co-covered peer. That works out to roughly 0.2 stories per week across a 135-day span. Their average consequence score of 6.3 runs above the beat's 6.2 for that window. This profile follows 3 Biotech stories mentioning Centers for Disease Control and Prevention across the period from February 27, 2026 to July 11, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 422 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Centers for Disease Control and Prevention. Shared-story counts are live from our verified record — not editorial picks.
With symptoms lasting weeks and no routine test, the cyclosporiasis outbreak across 18 states reveals a significant market opportunity for biotech companies developing rapid, point-of-care diagnostic assays. Over 1,250 cases in Michigan alone highlight the need for innovation.
South Carolina health officials have already allocated $1.6 million to contain a significant measles outbreak that shows no signs of immediate resolution. The expenditure highlights the massive economic burden of vaccine-preventable diseases on state public health infrastructures.
New York health authorities have issued a high-level alert regarding the accelerated spread of a deadly, drug-resistant fungal pathogen across healthcare facilities. The pathogen, identified as Candida auris, poses a severe threat to immunocompromised patients and highlights a critical gap in the current antifungal pharmaceutical pipeline.
Centers for Disease Control and Prevention is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
